Michael S Kelly,Elisabeth M Sulaica,Craig J Beavers
Michael S Kelly
Statins remain the preferred agent to reduce low-density lipoprotein cholesterol (LDL-C) and lower atherosclerotic cardiovascular disease (ASCVD) risk. Additional nonstatin agents are recommended to further lower LDL-C among patients at hig...
Ultrasound and Magnetic Responsive Drug Delivery Systems for Cardiovascular Application [0.03%]
用于心血管应用的超声和磁响应药物输送系统
Bei Qian,Qiang Zhao,Xiaofeng Ye
Bei Qian
With the increasing insight into molecular mechanisms of cardiovascular disease, a promising solution involves directly delivering genes, cells, and chemicals to the infarcted myocardium or impaired endothelium. However, the limited deliver...
The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis [0.03%]
非布司他与别嘌醇对高尿酸血症患者血压及主要不良心血管事件的影响： meta 分析
Marie Barrientos-Regala,Renelene A Macabeo,Rosemarie Ramirez-Ragasa et al.
Marie Barrientos-Regala et al.
Increased uric acid levels have been known to be associated with different cardiovascular and renal diseases. Over the past few years, several studies have examined the role of urate-lowering therapy (ULT) in hypertension and major adverse ...
Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients [0.03%]
糖尿病和CYP2C19多态性协同削弱氯吡格雷在经皮冠状动脉介入治疗的急性冠脉综合征患者中的抗血小板活性与替格瑞洛相比
Mina W Mohareb,Mohamed AbdElghany,Hala F Zaki et al.
Mina W Mohareb et al.
Diabetes and CYP2C19 loss of function (LOF) alleles are associated with the variable antiplatelet activity of the prodrug clopidogrel. We conducted a randomized trial (NCT03613857) to compare the combined and individualized effects of diabe...
Randomized Controlled Trial
Journal of cardiovascular pharmacology. 2020 Oct;76(4):478-488. DOI:10.1097/FJC.0000000000000881 2020
Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice [0.03%]
senolytic药物navitoclax抑制血管紧张素II诱导的小鼠心力衰竭
Kangni Jia,Yang Dai,Ao Liu et al.
Kangni Jia et al.
Navitoclax, which is a type of senolytic drug, selectively eliminates senescent cells. This study aimed to evaluate the therapeutic potential of navitoclax in treatment of angiotensin II (Ang II)-induced heart failure in mice. Navitoclax or...
Dan Zhou,Yong Zhang,Junbao Du et al.
Dan Zhou et al.
Sulfur dioxide (SO2) was previously known as a harmful gas in air pollution. Recently, it was reported that SO2 can be endogenously generated in cardiovascular tissues. Many studies have revealed that endogenous SO2 has important physiologi...
Late Sodium Current in Atrial Cardiomyocytes Contributes to the Induced and Spontaneous Atrial Fibrillation in Rabbit Hearts [0.03%]
晚钠电流通过参与兔心房的诱发和自发性颤动的发生发展发挥作用
Yanpeng Chu,Qiaomei Yang,Lu Ren et al.
Yanpeng Chu et al.
Increased late sodium current (INa) induces long QT syndrome 3 with increased risk of atrial fibrillation (AF). The role of atrial late INa in the induction of AF and in the treatment of AF was determined in this study. AF parameters were m...
Katarzyna Kuczyńska,Magdalena Boncler
Katarzyna Kuczyńska
Fentanyl is a potent synthetic opioid used to alleviate severe and chronic pain, as well as an adjunct to general or local anesthesia. Although fentanyl has been used for decades, its full effects are still unknown. Its analgesic and anesth...
4-Methoxyphenyl (E)-3-(Furan-3-yl) Acrylate Inhibits Vascular Smooth Muscle Cell Proliferation [0.03%]
对甲氧基苯基(E)-3-(呋喃-3-基)丙烯酸酯抑制血管平滑肌细胞增殖
Seongho Han,Mina Son,Yunmi Lee et al.
Seongho Han et al.
The Cordyceps extract exhibits antiproliferative potential in vascular smooth muscle cells (SMCs) through the mitogen-activated protein kinase signaling pathway. In this study, we aimed to identify the active compounds in the Cordyceps extr...
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use [0.03%]
莱沃西蒙旦的有效性和安全性：SIMDAX临床应用20年的经验
Zoltán Papp,Piergiuseppe Agostoni,Julian Alvarez et al.
Zoltán Papp et al.
Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 2...